Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis

Publication Type:
Journal Article
Journal of Pharmacy and Pharmacology, 2017, 69 (12), pp. 1672 - 1683
Issue Date:
Filename Description Size
Tonin_et_al-2017-Journal_of_Pharmacy_and_Pharmacology.pdfPublished Version946.29 kB
Adobe PDF
Full metadata record
© 2017 Royal Pharmaceutical Society Objectives: Despite its broad spectrum, conventional amphotericin B (AB) is associated with serious adverse events. Lipid-based formulations may offer safer options. We aimed to synthesize the evidence of efficacy and safety of AB formulations. Methods: We performed a systematic review and network meta-analysis (NMA) to compare all available formulations: conventional AB; lipid complex or ABLC; colloidal dispersion or ABCD; liposomal or LAB; AB in Intralipid. Randomized controlled trials were searched in four databases. Cure, fever, chills, nephrotoxicity, death and drug discontinuation were assessed. NMA was based on Bayesian methods accounting for direct and indirect comparisons. Probability ranks estimating the best formulation were built for each outcome. The relative benefit–risk of formulations was assessed with stochastic multicriteria acceptability analyses (SMAA). Key findings: We identified 25 trials (n = 2996). No significant differences among drugs were observed for cure or death. All lipid-based formulations were safer than conventional AB for nephrotoxicity. AB-Intralipid was more tolerable than conventional AB and caused less chills than ABCD. AB-Intralipid was the best therapy (>60%) regarding nephrotoxicity, fever, chills and discontinuation. The scenario from SMAA favoured AB-Intralipid (81% acceptability). Conventional AB was secondary to all lipid-based formulations. Conclusions: Amphotericin B-Intralipid was identified as safer, cost-saving treatment in comparison with other formulations.
Please use this identifier to cite or link to this item: